Filing search / Ownership / VYNE Therapeutics Inc.

8-K

VYNE VYNE Therapeutics Inc.

13 Jan 25

Corporate Presentation January 2025

7:50am

8-K

VYNE VYNE Therapeutics Inc.

23 Dec 24

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

7:42am

S-8

VYNE VYNE Therapeutics Inc.

19 Dec 24

Registration of securities for employees

4:27pm

8-K

VYNE VYNE Therapeutics Inc.

12 Dec 24

Departure of Directors or Certain Officers

4:01pm

ARS

2023 FY

VYNE VYNE Therapeutics Inc.

12 Nov 24

Annual report to shareholders

4:06pm

8-K

1hibq6k g5z

7 Nov 24

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

8:03am

8-K

8v7zykjx1

12 Sep 24

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

8:01am

8-K

mfi x1cv1gode

14 Aug 24

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

8:04am

8-K

p8yb84iey91umxtlt

9 May 24

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

8:00am

EFFECT

pca86p2p6iq3mu

15 Mar 24

Notice of effectiveness

12:15am

S-8

8p5ms

1 Mar 24

Registration of securities for employees

5:15pm

8-K

cqbymtls

29 Feb 24

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

8:12am

8-K

nnhd2 ixknh

3 Jan 24

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

8:15am

S-8

0pdyn 699e

13 Dec 23

Registration of securities for employees

4:36pm